Nivolumab as first line treatment in combination with chemotherapy was approved in Japan after the CheckMate 649 [8] and ATTRACTION-4 [9] trials of its use in patients with human epidermal growth factor receptor 2 (HER2)-negative, treatment-naïve advanced or recurrent GC. This evidence concerns the gene ERBB2 and gastric cancer.